Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Cost of Revenue
Tibet Rhodiola Pharmaceutical Holding Co
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Cost of Revenue
-¥158.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
18%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Cost of Revenue
-¥542.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-15%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Cost of Revenue
-¥229.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-13%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Cost of Revenue
-¥137.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-15%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Cost of Revenue
-¥45.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-17%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Cost of Revenue
-¥27.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Cost of Revenue?
Cost of Revenue
-158.7m
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Cost of Revenue amounts to -158.7m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
18%
Over the last year, the Cost of Revenue growth was 23%. The average annual Cost of Revenue growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 7% over the past three years , 5% over the past five years , and 18% over the past ten years .